Literature DB >> 20811274

Functional CCR5 receptor protects patients with arthritis from high synovial burden of infecting Chlamydia trachomatis.

Hervé C Gérard1, Jessica A Stanich, Cynthia E Oszust, Judith A Whittum-Hudson, John D Carter, H Ralph Schumacher, Alan P Hudson.   

Abstract

INTRODUCTION: The CCR5 chemokine receptor occurs in a wild-type (wt) and a nonfunctional deleted form (Δ32). Reports suggested that Chlamydia-induced reproductive tract pathology is attenuated in women bearing Δ32. The authors asked whether the mutation affects synovial prevalence and burden of Chlamydia trachomatis.
METHODS: Polymerase chain reaction (PCR) defined CCR5 genotype in synovial tissue DNA from 218 individuals: 21 controls, 110 with reactive arthritis (ReA), 83 with undifferentiated oligoarthritis (UO), 4 with osteoarthritis (OA). Disease durations were 0.5 to 21 years. Additional PCR assays defined the presence of C trachomatis DNA. Bacterial load was assessed by real-time PCR in selected samples.
RESULTS: Five controls were wt/Δ32, 16 were wt/wt; 2 of 21 controls (both wt/wt) were PCR positive for C trachomatis. Eighty-five (44%) patients with arthritis were PCR positive for C trachomatis (69 ReA and 16 UO). For patients with ReA, 14 (13%) had wt/Δ32, 10 (71%) of whom were PCR positive. Nineteen patients with UO (23%) were wt/Δ32, with 1 (1%) PCR positive. No differences existed for gender or other factors. One patient with OA had wt/Δ32. In ReA and UO samples, wt/Δ32 heterozygotes had a 5- to 10-fold higher bacterial burden than did wt/wt patients (P = 0.03), regardless of diagnosis.
CONCLUSION: These results indicate that the wt/wt genotype is associated with attenuated synovial bacterial load compared with loads in wt/Δ32 patients. Although no alleles other than Δ32 were assessed, our data suggest that this allele provides little/no protection from ReA in patients infected with Chlamydia- but it may provide some protection in patients with UO. The basis of this possible differential effect of CCR5 genotype is under study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811274      PMCID: PMC2995821          DOI: 10.1097/MAJ.0b013e3181ee6a62

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  16 in total

1.  Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion.

Authors:  Erika L Barr; Sander Ouburg; Joseph U Igietseme; Servaas A Morré; Edith Okwandu; Francis O Eko; Godwin Ifere; Tesfaye Belay; Qing He; Deborah Lyn; Gift Nwankwo; James W Lillard; Carolyn M Black; Godwin A Ananaba
Journal:  J Microbiol Immunol Infect       Date:  2005-08       Impact factor: 4.399

Review 2.  The Black Death and AIDS: CCR5-Delta32 in genetics and history.

Authors:  S K Cohn; L T Weaver
Journal:  QJM       Date:  2006-08

3.  Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression.

Authors:  H C Gérard; P J Branigan; H R Schumacher; A P Hudson
Journal:  J Rheumatol       Date:  1998-04       Impact factor: 4.666

4.  Up-regulation of the JAK/STAT1 signal pathway during Chlamydia trachomatis infection.

Authors:  Sonya P Lad; Elaine Y Fukuda; Jiali Li; Luis M de la Maza; Erguang Li
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

5.  Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis.

Authors:  V Pokorny; F McQueen; S Yeoman; M Merriman; A Merriman; A Harrison; J Highton; L McLean
Journal:  Ann Rheum Dis       Date:  2004-08-26       Impact factor: 19.103

Review 6.  Role of infectious agents in systemic rheumatic diseases.

Authors:  H Amital; M Govoni; R Maya; P L Meroni; B Ori; Y Shoenfeld; A Tincani; F Trotta; P Sarzi-Puttini; F Atzeni
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

Review 7.  Bacterial triggers and autoimmune rheumatic diseases.

Authors:  H J Girschick; L Guilherme; R D Inman; K Latsch; M Rihl; Y Sherer; Y Shoenfeld; H Zeidler; S Arienti; A Doria
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

Review 8.  Role of CCR5 Delta32 bp deletion in RA and SLE.

Authors:  H A Martens; C G M Kallenberg; M Bijl
Journal:  Autoimmunity       Date:  2009-05       Impact factor: 2.815

9.  Differential CCR5Delta32 allelic frequencies in juvenile idiopathic arthritis subtypes: evidence for different regulatory roles of CCR5 in rheumatological diseases.

Authors:  I Scheibel; T Veit; A G Neves; L Souza; S Prezzi; S Machado; C Kohem; M Icarelli; R Xavier; J C Brenol; J A B Chies
Journal:  Scand J Rheumatol       Date:  2008 Jan-Feb       Impact factor: 3.641

10.  CCR5 deficiency increases risk of symptomatic West Nile virus infection.

Authors:  William G Glass; David H McDermott; Jean K Lim; Sudkamon Lekhong; Shuk Fong Yu; William A Frank; John Pape; Ronald C Cheshier; Philip M Murphy
Journal:  J Exp Med       Date:  2006-01-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.